<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35387475</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-660X</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of clinical microbiology</Title><ISOAbbreviation>J Clin Microbiol</ISOAbbreviation></Journal><ArticleTitle>Multicenter Evaluation of the BioFire Respiratory Panel 2.1 (RP2.1) for Detection of SARS-CoV-2 in Nasopharyngeal Swab Samples.</ArticleTitle><Pagination><StartPage>e0006622</StartPage><MedlinePgn>e0006622</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00066-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jcm.00066-22</ELocationID><Abstract><AbstractText>As the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) begins to overlap with the traditional respiratory season in the Northern Hemisphere, simultaneous testing for SARS-CoV-2 and the other common causes of respiratory infections is imperative. This has led to the development of multiplex respiratory assays that include SARS-CoV-2 as a target. One such assay is the BioFire respiratory panel 2.1 (RP2.1), which is an expansion of the original BioFire FilmArray respiratory panel 2 (RP2) to include SARS-CoV-2. In this multicenter evaluation, we assessed the performance characteristics of the BioFire RP2.1 for the detection of SARS-CoV-2. One or more targets on the panel were detected in 19.3% (101/524) of specimens tested, with SARS-CoV-2 detected in 12.6% (66/524) of specimens. Human rhinovirus/enterovirus was also detected in 32.7% (33/101) and adenovirus in 3.0% (3/101) of positive specimens, with one dual positive for both SARS-CoV-2 and adenovirus being detected. A further breakdown of pathogens by age revealed a 4-fold predominance of human rhinovirus/enterovirus in subjects 0 to 18&#x2009;years of age, whereas in all other age groups, SARS-CoV-2 was clearly the predominant pathogen. Overall, SARS-CoV-2 results obtained from the BioFire RP2.1 were highly concordant with the composite result, exhibiting 98.4% (61/62) positive percent agreement (95% confidence interval [CI], 91.4 to 99.7%) and 98.9% (457/462) negative percent agreement (95% CI, 97.5 to 99.5%) with further analysis of discordant results suggesting that the concentration of SARS-CoV-2 in the specimens was near the limit of detection (LoD) for both the BioFire RP2.1 and the comparator assays. Overall, the BioFire RP2.1 exhibited excellent performance in the detection of SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0002-0767-6826</Identifier><AffiliationInfo><Affiliation>Infectious Disease Diagnostics, Northwell Health Laboratories, Lake Success, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Infectious Disease Diagnostics, Northwell Health Laboratories, Lake Success, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Infectious Disease Diagnostics, Northwell Health Laboratories, Lake Success, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manji</LastName><ForeName>Ryhana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Infectious Disease Diagnostics, Northwell Health Laboratories, Lake Success, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silbert</LastName><ForeName>Suzane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tampa General Hospitalgrid.416892.0, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Amorce</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tampa General Hospitalgrid.416892.0, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harington</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Loyola University, Maywood, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinley</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Loyola University, Maywood, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kensinger</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>BioFire Diagnostics, LLC, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neff</LastName><ForeName>Crissy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>BioFire Diagnostics, LLC, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Daisy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>BioFire Diagnostics, LLC, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Microbiol</MedlineTA><NlmUniqueID>7505564</NlmUniqueID><ISSNLinking>0095-1137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C072178">RP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019204" MajorTopicYN="N">GTP-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="Y">Viruses</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BioFire</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">nasopharyngeal swabs</Keyword><Keyword MajorTopicYN="N">respiratory panel 2.1</Keyword><Keyword MajorTopicYN="N">respiratory pathogens</Keyword></KeywordList><CoiStatement>The authors declare a conflict of interest. All authors received research funding from BioFire for this study. Additionally, G.B. has given educational seminars sponsored by BioFire and has also served on an advisory panel.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35387475</ArticleId><ArticleId IdType="pmc">PMC9116161</ArticleId><ArticleId IdType="doi">10.1128/jcm.00066-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moriyama M, Hugentobler WJ, Iwasaki A. 2020. Seasonality of respiratory viral infections. Annu Rev Virol 7:83&#x2013;101. doi:10.1146/annurev-virology-012420-022445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-012420-022445</ArticleId><ArticleId IdType="pubmed">32196426</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DA, Sherman AC, Kanjilal S. 2020. Influenza in the COVID-19 era. JAMA 324:1342&#x2013;1343. doi:10.1001/jama.2020.14661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.14661</ArticleId><ArticleId IdType="pubmed">32797145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Quinn J, Pinsky B, Shah NH, Brown I. 2020. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA 323:2085&#x2013;2086. doi:10.1001/jama.2020.6266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6266</ArticleId><ArticleId IdType="pmc">PMC7160748</ArticleId><ArticleId IdType="pubmed">32293646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, Li Q, Gu S, Xu T, Li Y, Lu B, Zhan Q. 2020. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis 26:1324&#x2013;1326. doi:10.3201/eid2606.200299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2606.200299</ArticleId><ArticleId IdType="pmc">PMC7258479</ArticleId><ArticleId IdType="pubmed">32160148</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang B-R, Lin Y-L, Wan C-K, Wu J-T, Hsu C-Y, Chiu M-H, Huang C-H. 2021. Co-infection of influenza B virus and SARS-CoV-2: a case report from Taiwan. J Microbiol Immunol Infect 54:336&#x2013;338. doi:10.1016/j.jmii.2020.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.06.011</ArticleId><ArticleId IdType="pmc">PMC7324913</ArticleId><ArticleId IdType="pubmed">32646801</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado-Pay&#xe1;n E, Montagud-Marrahi E, Torres-Elorza M, Bodro M, Blasco M, Poch E, Soriano A, Pi&#xf1;eiro GJ. 2020. SARS-CoV-2 and influenza virus co-infection. Lancet 395:e84. doi:10.1016/S0140-6736(20)31052-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31052-7</ArticleId><ArticleId IdType="pmc">PMC7200126</ArticleId><ArticleId IdType="pubmed">32423586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Wang H, Su Z, Li W, Yang D, Deng F, Chen J. 2020. Co-infection of SARS-CoV-2 and influenza virus in early stage of the COVID-19 epidemic in Wuhan, China. J Infect 81:e128&#x2013;e129. doi:10.1016/j.jinf.2020.05.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.041</ArticleId><ArticleId IdType="pmc">PMC7255712</ArticleId><ArticleId IdType="pubmed">32474045</ArticleId></ArticleIdList></Reference><Reference><Citation>Azekawa S, Namkoong H, Mitamura K, Kawaoka Y, Saito F. 2020. Co-infection with SARS-CoV-2 and influenza A virus. IDCases 20:e00775. doi:10.1016/j.idcr.2020.e00775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2020.e00775</ArticleId><ArticleId IdType="pmc">PMC7184249</ArticleId><ArticleId IdType="pubmed">32368495</ArticleId></ArticleIdList></Reference><Reference><Citation>Leber AL, Everhart K, Daly JA, Hopper A, Harrington A, Schreckenberger P, McKinley K, Jones M, Holmberg K, Kensinger B. 2018. Multicenter evaluation of BioFire FilmArray respiratory panel 2 for detection of viruses and bacteria in nasopharyngeal swab samples. J Clin Microbiol 56:e01945-17. doi:10.1128/JCM.01945-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01945-17</ArticleId><ArticleId IdType="pmc">PMC5971546</ArticleId><ArticleId IdType="pubmed">29593057</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe RG. 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statist Med 17:857&#x2013;872. doi:10.1002/(SICI)1097-0258(19980430)17:8&lt;857::AID-SIM777&gt;3.0.CO;2-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19980430)17:8&lt;857::AID-SIM777&gt;3.0.CO;2-E</ArticleId><ArticleId IdType="pubmed">9595616</ArticleId></ArticleIdList></Reference><Reference><Citation>Creager HM, Cabrera B, Schnaubelt A, Cox JL, Cushman-Vokoun AM, Shakir SM, Tardif KD, Huang M-L, Jerome KR, Greninger AL, Drobysheva D, Spaulding U, Rogatcheva M, Bourzac KM, Hinrichs SH, Broadhurst MJ, Fey PD. 2020. Clinical evaluation of the BioFire respiratory panel 2.1 and detection of SARS-CoV-2. J Clin Virol 129:104538. doi:10.1016/j.jcv.2020.104538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104538</ArticleId><ArticleId IdType="pmc">PMC7336953</ArticleId><ArticleId IdType="pubmed">32650276</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NA. 2020. Pediatric COVID-19: systematic review of the literature. Am J Otolaryngol 41:102573. doi:10.1016/j.amjoto.2020.102573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2020.102573</ArticleId><ArticleId IdType="pmc">PMC7833675</ArticleId><ArticleId IdType="pubmed">32531620</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E, Zhen W, Manji R, Schron D, Duong S, Berry GJ. 2020. Analytical and clinical comparison of three nucleic acid amplification tests for SARS-CoV-2 detection. J Clin Microbiol 58:e01134-20. doi:10.1128/JCM.01134-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01134-20</ArticleId><ArticleId IdType="pmc">PMC7448672</ArticleId><ArticleId IdType="pubmed">32571894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa HH, Hardick J, Morehead E, Miller J-A, Gaydos CA, Manabe YC. 2020. Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays. J Clin Virol 130:104578. doi:10.1016/j.jcv.2020.104578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104578</ArticleId><ArticleId IdType="pmc">PMC7405824</ArticleId><ArticleId IdType="pubmed">32777761</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen W, Manji R, Smith E, Berry GJ. 2020. Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in nasopharyngeal specimens. J Clin Microbiol 58:e00743-20. doi:10.1128/JCM.00743-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00743-20</ArticleId><ArticleId IdType="pmc">PMC7383517</ArticleId><ArticleId IdType="pubmed">32341143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen W, Smith E, Manji R, Schron D, Berry GJ. 2020. Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2. J Clin Microbiol 58:e00783-20. doi:10.1128/JCM.00783-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00783-20</ArticleId><ArticleId IdType="pmc">PMC7383520</ArticleId><ArticleId IdType="pubmed">32332061</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL. 2020. Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol 58:e00821-20. doi:10.1128/JCM.00821-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00821-20</ArticleId><ArticleId IdType="pmc">PMC7383518</ArticleId><ArticleId IdType="pubmed">32350048</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention.
Symptoms and care for RSV. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/rsv/about/symptoms.html. Retrieved 14 September 2021.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention.
Flu symptoms &amp; diagnosis. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/flu/symptoms/index.html. Retrieved 6 January 2022.</Citation></Reference><Reference><Citation>Neher RA, Dyrdak R, Druelle V, Hodcroft EB, Albert J. 2020. Potential impact of seasonal forcing on a SARS-CoV-2 pandemic. Swiss Med Wkly 150:w20224. doi:10.4414/smw.2020.20224.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2020.20224</ArticleId><ArticleId IdType="pubmed">32176808</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. 2021. Increased interseasonal respiratory syncytial virus (RSV) activity in parts of the southern United States. Centers for Disease Control and Prevention, Atlanta, GA. https://emergency.cdc.gov/han/2021/han00443.asp. Retrieved 14 September 2021.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. 2020. Testing guidance for clinicians when SARS-CoV-2 and influenza viruses are co-circulating. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians.htm. Retrieved 15 September 2021.</Citation></Reference><Reference><Citation>Zhen W, Berry GJ. 2020. Development of a new multiplex real-time RT-PCR assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. J Mol Diagn 22:1367&#x2013;1372. doi:10.1016/j.jmoldx.2020.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2020.09.004</ArticleId><ArticleId IdType="pmc">PMC7501774</ArticleId><ArticleId IdType="pubmed">32961315</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xf6;rz D, Pfefferle S, Grunwald M, Fischer N, Aepfelbacher M, L&#xfc;tgehetmann M. 2021. Modifying a diagnostic SARS-CoV-2 spike PCR to turn a Del69/70 dropout into a discriminatory on-target assay. J Mol Diagn 23:777&#x2013;778. doi:10.1016/j.jmoldx.2021.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2021.03.007</ArticleId><ArticleId IdType="pmc">PMC8041738</ArticleId><ArticleId IdType="pubmed">33862239</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. 2021. FDA de novo authorization for BioFire respiratory panel 2.1 (RP2.1). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN200031. Retrieved 23 February 2022.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. 2021. FDA emergency use authorization for NeuMoDx SARS-CoV-2 assay. Food and Drug Administration, Washington, DC. https://www.fda.gov/media/136566/download. Retrieved 23 February 2022.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. 2021. FDA emergency use authorization for BioFire COVID-19 test. Food and Drug Administration, Washington, DC. https://www.fda.gov/media/136356/download. Retrieved 23 February 2022.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. 2020. FDA emergency use authorization for New York SARS-CoV-2 real-time RT-PCR diagnostic panel. Food and Drug Administration, Washington, DC. https://www.fda.gov/media/135661/download. Retrieved 23 February 2022.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. 2021. FDA emergency use authorization for Aptima SARS-CoV-2 assay. Food and Drug Administration, Washington, DC. https://www.fda.gov/media/138097/download. Retrieved 23 February 2022.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. 2021. FDA emergency use authorization for Abbott RealTime SARS-CoV-2. Food and Drug Administration, Washington, DC. https://www.fda.gov/media/136255/download. Retrieved 23 February 3033.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. 2021. FDA emergency use authorization for Expert Xpress SARS-CoV-2. Food and Drug Administration, Washington, DC. https://www.fda.gov/media/136316/download. Retrieved 23 February 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>